| Literature DB >> 34400886 |
Vito Crincoli1, Mariangela Cannavale2, Angela Pia Cazzolla3, Mario Dioguardi3, Maria Grazia Piancino2, Mariasevera Di Comite1.
Abstract
Aim: Inflammatory idiopathic myopathies (IIMs) are inflammatory processes affecting skeletal musculature and extramuscular organs. Temporomandibular disorders (TMD) involve jaw muscles and temporomandibular joint. The aim of this observational study was to investigate the prevalence of the main TMD symptoms and signs as well as oral implications in IIM patients.Entities:
Keywords: inflammatory idiopathic myopathies; oral signs and symptoms; temporomandibular disorders
Mesh:
Year: 2021 PMID: 34400886 PMCID: PMC8364457 DOI: 10.7150/ijms.45226
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Classification and duration of myositis
| Classification | Patients |
|---|---|
| DM, n (%) | 22 (40.7%) |
| PM, n (%) | 29 (53.7%) |
| IBM, n (%) | 3 (5.6%) |
| Disease duration, years (mean and ± SD) | 3,7 ± 6,4 |
Demographic data in patient groups and controls
| Demographic Data | Patients | Controls | χ2 | |
|---|---|---|---|---|
| Mean age ± SD | 59 ± 13.4 | 59 ± 13.4 | ||
|
| ||||
| Males | 12 (22.2%) | 11 (20.4%) | 0.05 | > 0.05 |
| Females | 42 (78.8%) | 43 (79.6%) | ||
|
| ||||
| Married | 41 (75.9%) | 35 (64.8%) | 3.1 | > 0.05 |
| Unmarried | 7 (13.0%) | 9 (16.7%) | ||
| Widowers | 3 (5.6%) | 8 (14.8%) | ||
| Divorced | 3 (5.6 %) | 2 (3.7%) | ||
|
| ||||
| Primary school | 12 (22.2%) | 13 (24.1%) | 8.7 | > 0.05 |
| Middle School | 21 (38.9%) | 9 (16.7%) | ||
| High school | 13 (24.1%) | 19 (35.2%) | ||
| Graduation | 7 (13%) | 13 (24.1%) | ||
|
| ||||
| Unemployed | 2 (3.7%) | 1 (1.9%) | 13.5 | > 0.05 |
| Housewives | 17 (31.5%) | 20 (37%) | ||
| Public employees | 6 (11.1%) | 16 (29.6%) | ||
| Freelancers | 2 (3.7%) | 5 (9.3%) | ||
| Students | 1 (1.9%) | 0 | ||
| Retirees | 20 (37%) | 11 (20.4%) | ||
| Workmen/craftsmen | 6 (11.1%) | 1 (1.9%) |
Laboratory tests in the patient group
| Laboratory examinations | Patients |
|---|---|
| CPK U/L (mean and ± SD) | 312 ± 1134.2 |
| LDH U/L (mean and ± SD) | 330,8 ± 142.6 |
| VES mm/h (mean and ± SD) | 24,8 ±22.5 |
| Anti-synthetase antibodies, n (%) | 42 (77.8%) |
| Associated myositis antibodies, n (%) | 41 (75.9%) |
Figure 1Mean values (± SD) of MMT-8 and MMT-TIGHT evaluations in patient group and controls.
Comorbidity in patient groups and controls
| Comorbidity | Patients | Controls | Test | |
|---|---|---|---|---|
| Osteopenia/osteoporosis | 12 (22.2%) | 1 (1.9%) | χ2 =10,5 |
|
| Thyroid dysfunction | 18 (33.3%) | 6 (11.1%) | χ2 =7,7 |
|
| Blood diseases | 4 (7.4%) | 0 | Fisher's exact test |
|
| Heart diseases | 13 (24.1%) | 4 (7.5%) | χ2 =5,6 |
|
| Liver diseases | 12 (22.2%) | 0 | χ2 =13,5 |
|
| Gastrointestinal diseases | 7 (13.0%) | 0 | Fisher's exact test |
|
| Hypovitaminosis | 4 (7.4%) | 1 (1.9%) | Fisher's exact test | > 0.05 |
| Kidney diseases | 3 (5.6%) | 1 (1.9%) | Fisher's exact test | > 0.05 |
| Dyslipidemia | 2 (3.7%) | 2 (3.7%) | Fisher's exact test | > 0.05 |
| Diabetes | 5 (9.3%) | 5 (9.3%) | χ2 =0 | > 0.05 |
| Lung diseases | 3 (5.6%) | 0 | Fisher's exact test | > 0.05 |
| Hypertension | 20 (37.0%) | 17 (31.5%) | χ2 =0,4 | > 0.05 |
| Diseases of the nervous system | 4 (7.4%) | 1 (1.9%) | Fisher's exact test | > 0.05 |
| Valvulopathy | 2 (3.7%) | 0 | Fisher's exact test | > 0.05 |
| Other comorbidities | 30 (55.6%) | 9 (16.7%) | χ2 =17,6 |
|
Manifestations of the disease in patient group and controls
| Manifestations of pathology | Patients | Controls | χ2 | |
|---|---|---|---|---|
| Raynaud | 17 (31.5%) | 0 | 20 |
|
| Skin lesions | 27 (50%) | 0 | 36 |
|
| ILD | 21 (38.9%) | 0 | 26 |
|
| Arthritis | 14 (25.9%) | 3 (5.6%) | 16 |
|
Drugs for treatment of myositis
| Drugs | Patients | Controls | Test | |
|---|---|---|---|---|
| Corticosteroids | 68.5% | 0% | χ2 =56 |
|
| Methotrexate | 31.5% | 0% | χ2 =20 |
|
| Azathioprine | 29.6% | 0% | χ2 =18,8 |
|
| Mycophenolate | 18.5% | 0% | χ2 =11 |
|
| Immunoglobulin | 13.0% | 0% | Fisher |
|
| Cyclosporine | 3.7% | 0% | χ2 =2 | > 0.05 |
| Hydroxychloroquine | 3.7% | 0% | Fisher | > 0.05 |
| Cyclophosphamide | 1.9% | 0% | Fisher | > 0.05 |
| Tocilizumab | 3.7% | 0% | Fisher | > 0.05 |
| Rituximab | 9.3% | 0% | Fisher |
|
Drugs taken in the patient groups and controls
| Drugs | Patients | Controls | Test | |
|---|---|---|---|---|
| Antihypertensive | 29.6% | 27,8% | χ2 =0,04 | > 0.05 |
| Myorelaxants | 14.8% | 0% | Fisher |
|
| Bisphosphonates | 11.1% | 1.9% | Fisher | > 0.05 |
| Diuretics | 9.3% | 1.9% | Fisher | > 0.05 |
| Fans/antirheumatics | 9.3% | 0% | Fisher |
|
| Opioid analgesics | 0% | 1.9% | Fisher | > 0.05 |
| Antidepressants | 1.9% | 0% | Fisher | > 0.05 |
| Antidiabetic | 5.6% | 9.3% | Fisher | > 0.05 |
| ASA | 7.4% | 1.9% | Fisher | > 0.05 |
| BDZ | 3.7% | 0% | Fisher | > 0.05 |
| Statins | 1.9% | 5.6% | Fisher | > 0.05 |
| Vasodilators | 1.9% | 0% | Fisher | > 0.05 |
| Others | 81.5% | 5.6% | χ2 =63 |
|
Subjective complaints of oral discomfort in patient group and control
| Oral symptoms | Patients | Controls | χ2 | |
|---|---|---|---|---|
| Xerostomia | 29 (54.7%) | 8 (15.1%) | 18.310 |
|
| Dysgeusia | 12 (22.6%) | 2 (3.8%) | 8.230 |
|
| Stomatodynia | 5 (9.4%) | 0 (0%) | 5.248 |
|
| Dysphagia | 26 (48.1%) | 0 (0%) | 34.450 |
|
TMJ symptoms in patient groups and controls
| TMJ symptoms | Patients | Controls | χ2 | |
|---|---|---|---|---|
| Tinnitus | 21 (38.9%) | 13 (24.1%) | 3 | > 0.05 |
| Arthralgia | 9 (16.7%) | 10 (18.5%) | 0,06 | > 0.05 |
| Temporal headache | 17 (31.5%) | 14 (25.9%) | 0,5 | > 0.05 |
Mean values and ±SD of Numeric Pain Rating Scale (NPRS) in patient groups and controls (Range values 0-10; Unpaired T-test)
| Patients | Controls | ||
|---|---|---|---|
| Arthralgia | 1,04 ±2,52 | 0,56 ±1,38 | < 0.05 |
| Temporal headache | 1,86 ±3,15 | 0,74 ±1,48 |
|
Muscle symptoms in patient groups and controls
| Muscular symptoms | Patients | Controls | χ2 | |
|---|---|---|---|---|
| Digastric | 17 (31.5%) | 2 (3.7%) | 14 |
|
| Deep Masseter | 25 (46.3%) | 8 (14.8%) | 13 |
|
| Superficial masseter | 25 (46.3%) | 14 (25.9%) | 5 |
|
| Mylohyoid | 17 (31.5%) | 3 (5.6%) | 12 |
|
| Subhyoid muscles | 30 (55.6%) | 0 | 41 |
|
| External pterygoid | 34 (63%) | 34 (63%) | 0 | > 0.05 |
| Internal pterygoid | 30 (56.6%) | 15 (27.8%) | 9 |
|
| Sternocleidomastoid | 22 (40.7%) | 9 (16.7%) | 8 |
|
| Anterior temporal | 13 (24.5%) | 16 (29.6%) | 0,3 | > 0.05 |
| Middle temporal | 12 (22.2%) | 9 (16.7%) | 0,5 | > 0.05 |
| Posterior temporal | 11 (20.4%) | 10 (18.5%) | 0,05 | > 0.05 |
| Trapezius | 29 (26.9%) | 0 | 40 |
|
| Neck/shoulder pain | 39 (72.2%) | 2 (3.7%) | 54 |
|
| Masticatory muscle pain | 14 (25.9%) | 5 (9.3%) | 5 |
|
Mean values and ±SD of Numeric Pain Rating Scale (NPRS) in patient groups and controls (Range values 0-10; Unpaired T-test)
| Patients | Controls | ||
|---|---|---|---|
| Masticatory muscles | 0.96 ±2.14 | 0.20 ±0.68 |
|
| Neck/shoulder | 3.39 ±3.42 | 0.15 ± 0.79 |
|
| Muscle pain during function | 1.39 ±2.97 | 1.28 ±1.90 | < 0.05 |
Figure 2Mean values (±SD) of intensity of perceived myofascial pain under palpation in patient groups and controls according to the following scale: 0= No Pain or just pressure, 1= Mild Pain, 2 = Moderate Pain, 3= Severe Pain (Unpaired T-test; ).
Oral signs in patient groups and controls
| Oral signs | Patients | Controls | Test | |
|---|---|---|---|---|
| Erythema | 1 (1.9%) | 0 | Fisher | > 0.05 |
| Ulcers | 0 | 9 (16.7%) | Fisher |
|
| Cheilitis | 0 | 4 (7.4%) | Fisher |
|
Partial or total edentulism in patient and control group
| Edentulism | |||
|---|---|---|---|
| Patients | Controls | χ2 |
|
| 13 (24.1%) | 0 | 14.8 |
|
TMJ sounds in patient groups and control
| Joint noise | Patients | Controls | Test | |
|---|---|---|---|---|
| Click | 6 (11.1%) | 6 (11.1%) | 0 | > 0.05 |
| Crackling | 6 (11.1%) | 5 (9.3%) | 0,1 | > 0.05 |
| Mutual click | 2 (3.7%) | 8 (14.8%) | 4 |
|
| Opening click | 7 (13%) | 15 (27.8%) | Fisher |
|
Figure 3Mean values (±SD) of active opening and endfeel (Unpaired T-test).
Figure 4Mean values (±SD) of right and left laterality and protrusion (Unpaired T-test).
Qualitative opening in patient groups and controls
| Quality of opening | Patients | Controls | χ2 | |
|---|---|---|---|---|
| Deviation | 3 (5.6%) | 29 (53.7%) | 30 |
|
| Deflection | 5 (9.3%) | 2 (3.7%) | 1,3 | > 0.05 |
Bruxism in patient groups and controls
| Patients | Controls | TEST | ||
|---|---|---|---|---|
| Bruxism (S/A) | 0 | 8 (14.8%) | Fisher |
|
| Clenching | 16 (29.6%) | 19 (35.2%) | χ2 = 0.3 | > 0.05 |
| Wear facets | 18 (33.3%) | 19 (35.2%) | χ2 = 0.04 | > 0.05 |
| Oral frictional hyperkeratosis | 11 (20.4%) | 9 (16.7%) | χ2 = 0.2 | > 0.05 |
| Indentations of the tongue | 7 (13%) | 18 (33.3%) | χ2 = 6.2 |
|
Cronbach's alpha values and confidence intervals referred to patients and control group pooled together
| Sets of variables | Cronbach's alpha values | 95% bootstrap confidence intervals |
|---|---|---|
| Symptoms | 0.69 | 0.61-0.71 |
| Signs | 0.69 | 0.60-0.77 |
| Symptoms + signs | 0.74 | 0.68-0.81 |
Oral signs and symptoms in DM patients and controls
| Dermatomyositis | Patients | Controls |
|---|---|---|
| TMJ symptoms | 18 (81.8%) | 40 (74.07%) |
| Muscle symptoms | 18 (81.8%) | 40 (74.07%) |
| Oral signs | 9 (40.9%) | 33 (61.11%) |
Oral signs and symptoms in PM patients and controls
| Polymyositis | Patients | Controls |
|---|---|---|
| TMJ symptoms | 23 (79.3%) | 40 (74.07%) |
| Muscle symptoms | 19 (65.5%) | 40 (74.07%) |
| Oral signs | 12 (41.37%) | 33 (61.11%) |
Oral signs and symptoms in IBM patients and controls
| Inclusion body myositis | Patients | Controls |
|---|---|---|
| TMJ symptoms | 3 (100%) | 40 (74.07%) |
| Muscle symptoms | 3 (100%) | 40 (74.07%) |
| Oral signs | 3 (100%) | 33 (61.11%) |